Anti-Mullerian Hormone (AMH) testing for female patients who will or have received gonadotoxic treatment

Kessels, S, Mittal, R, Morona, J, Newton, S, Schubert, C, Milverton, J, Merlin, T
Record ID 32018000550
Original Title: Application 1434
Authors' results and conclusions: No direct evidence was identified to determine the safety and incremental effectiveness of anti-Mullerian hormone (AMH) testing in addition to other standard tests, or compared to other standard tests alone, in patients prior to or following completion of gonadotoxic therapy. The test is generally considered to be safe. Different AMH assays correlated highly with each other, although they differed greatly in sensitivity. AMH testing does provide some incremental information for predicting ovarian functioning. However, the relationship between AMH testing and the most clinically relevant outcome of pregnancy or a live birth was not significant. No studies were identified which reported on how the prognostic information is being used in the target population, i.e. no evidence on how AMH results impact on the management of women undergoing gonadotoxic treatment. In women undergoing IVF, but not the target population, there is evidence that AMH values may influence the starting dosage of recombinant follicle-stimulating hormone or human menopausal gonadotropin during ovarian hyperstimulation for the retrieval of oocytes. However, the studies showed a lack of standardisation regarding how the AMH score was used or should be used in this broader population. The major challenge for clinicians attempting to interpret AMH values for use in clinical care is the lack of standardisation. It is recommended that clinicians should always use the same laboratory to avoid problems with result interpretation. It is also critical to understand how that laboratory calibrates their clinical thresholds to ensure accurate interpretation of the result. A good quality assurance program would be essential for implementation and development of standardised clinically relevant thresholds for AMH testing in Australia.
Project Status: Completed
Year Published: 2018
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Australia
MeSH Terms
  • Anti-Mullerian Hormone
  • Neoplasms
  • Ovarian Follicle
  • Cryopreservation
  • Fertility Preservation
Organisation Name: Adelaide Health Technology Assessment
Contact Address: School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
Contact Email:
Copyright: Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.